PlainPharmaWatch

CMS Open Payments · Tool

Organogenesis Inc. vs Amneal Pharmaceuticals LLC

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Amneal Pharmaceuticals LLC has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 194, versus 167 for the other company. Its single largest recorded recipient represents 0.1% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Organogenesis Inc.
HHI 167 · top recipient 0.1%
Ranked #1,598 of 1,838 companies by HHI
Amneal Pharmaceuticals LLC
HHI 194 · top recipient 0.1%
Ranked #1,567 of 1,838 companies by HHI

Payment Overview

Company A

Organogenesis Inc.

Total Payments
$3.1M
% of Industry
0.0%
Transactions
24,397
Avg per Transaction
$127.79
Recipients
24,238
Avg per Recipient
$128.63
Payment Types
7
Top Payment Type
Food and Beverage
Total Payments
$3.1M
% of Industry
0.0%
Transactions
20,499
Avg per Transaction
$151.63
Recipients
20,418
Avg per Recipient
$152.23
Payment Types
8
Top Payment Type
Honoraria

Highlighted values indicate the higher figure for each metric.

Total payments compared

Organogenesis Inc. vs Amneal Pharmaceuticals LLC - total reported payments in CMS Open Payments PY2024

Organogenesis Inc.$3.1MAmneal Pharmaceuticals LLC$3.1M

Payment Types Breakdown

Organogenesis Inc.

Food and Beverage $739.1K

23.7%

Compensation for Services Other Than Consulting $705.1K

22.6%

Consulting Fee $445.3K

14.3%

Travel and Lodging $131.1K

4.2%

Space Rental or Facility Fees $22.6K

0.7%

Debt Forgiveness $6.5K

0.2%

Amneal Pharmaceuticals LLC

Honoraria $655.8K

21.1%

Food and Beverage $468.0K

15.1%

Consulting Fee $316.5K

10.2%

Education $259.1K

8.3%

Travel and Lodging $105.7K

3.4%

Grant $67.1K

2.2%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Organogenesis Inc.

  1. 1

    VIPUL DEV

    $135,584.69 · 52 txns

  2. 2

    AMY TUCKER

    $119,175.42 · 151 txns

  3. 3

    SCOTT JAMES

    $84,049.24 · 8 txns

  4. 4

    ROBERT CLEMENCY

    $78,714.48 · 74 txns

  5. 5

    DANIEL KAPP

    $60,131.89 · 28 txns

Amneal Pharmaceuticals LLC

  1. 1

    MARIA OSPINA

    $112,645.53 · 91 txns

  2. 2

    STUART ISAACSON

    $88,922.64 · 41 txns

  3. 3

    LAXMAN BAHROO

    $78,311.35 · 76 txns

  4. 4

    RAMSEY A FALCONER

    $78,004.81 · 59 txns

  5. 5

    ROBERT HAUSER

    $77,991.79 · 39 txns

Summary Comparison

Metric Organogenesis Inc. Amneal Pharmaceuticals LLC
Total Payments $3.1M $3.1M
% of Industry Total 0.0% 0.0%
Transaction Count 24,397 20,499
Avg per Transaction $127.79 $151.63
Recipient Count 24,238 20,418
Avg per Recipient $128.63 $152.23
Payment Type Count 7 8
Top Payment Type Food and Beverage Honoraria

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.